Updates
  • November 26, 2024

    Adaptilens was well represented at the Ophthalmology Innovation Source XIV in San Diego where our CEO Liane Clamen spoke on the panel "Future of Anterior Innovation: A Panel of Disruptors and Visionaries." Thank you Anthony Wallace - Bausch + Lomb Surgical for inviting our CEO and facilitating an inspiring discussion.

  • November 19, 2024

    Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.

    Read More
  • November 12, 2024

    We’re excited to share that Adaptilens has been nominated for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for this nomination. We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. Read the full announcement here: https://lnkd.in/e548JKAk #NEVYsSurvivor #NEVCA #Innovation

  • November 3, 2024

    Adaptilens is pleased to announce that our CEO, Dr. Liane Clamen, was invited to participate in a panel discussion on the "Future of Anterior Innovation" at the Ophthalmology Innovation Summit next month.

  • October 3, 2024

    It was a privilege to present Adaptilens at the International Society of Presbyopia Conference in Barcelona. I enjoyed connecting with leaders and innovators in the field.